Aurobindo Pharma in Pole Position for $5.5 Billion Zentiva Buyout
Indian pharmaceutical major Aurobindo Pharma has emerged as the front-runner to acquire Zentiva , the Czech-based generic drugmaker owned by Advent International , in a deal that could be valued at $5.5 billion , according to reports from The Economic Times . If finalized, this w…
Indian pharmaceutical major Aurobindo Pharma has emerged as the front-runner to acquire Zentiva, the Czech-based generic drugmaker owned by Advent International, in a deal that could be valued at $5.5 billion, according to reports from The Economic Times.
If finalized, this would mark the largest overseas acquisition ever by an Indian pharma company, cementing Aurobindo’s position among the top global players in the generics and biosimilars space.
Current Status of the Deal
Aurobindo clarified in an exchange filing that no binding agreement has been signed yet, underscoring that negotiations remain ongoing. Markets reacted cautiously, with Aurobindo shares sliding as much as 4.7% intraday, before settling down about 3.7%.
Strategic Rationale
Financing the Buyout
Reports suggest Aurobindo has secured a $4.75 billion bridge loan from MUFG Bank, with the remainder—around $800 million—to be funded through internal resources. This mix highlights the ambitious scale of the potential transaction and the company’s appetite for global expansion.
Investor Perspective
While the acquisition promises to elevate Aurobindo into a higher league of global generics and biosimilar players, investor caution is evident:
Written by
Tom Whitmore
Senior correspondent · Real Estate & Private Companies
Tom has interviewed most of the operators reshaping the Gulf skyline — and a few of the ones who tried and didn't. His beat is real estate, commodities, manufacturing, and the founder-led private companies that never bother to list. He knows which buildings and balance sheets survive a downturn before the spreadsheet does. Based in Dubai. Reach out at tom.whitmore@theplatinumcapital.com.
